Newsletter: Read the latest issue
See the academic requirements for the College of Osteopathic Medicine
Find the information you need to conduct your research and academic studies
See KCU's beautiful campus
View abstracts and watch webcasts
Oct. 22 | 5:30 p.m.
Union Station, Sprint Festival Plaza
Kansas City, Missouri
Flavia Costa, Ph.D., Research Instructor, College of Biosciences, KCUMB, presents Regulating Fetal Hemoglobin and Erythropoiesis as an Intervention for Sickle Cell Disease.
Sickle Cell Disease (SCD) is a common genetic disorder that affects approximately 1 in 1,800 newborns in the U.S. including 1 in 400 African-American infants. High levels of fetal hemoglobin (HbF - g-globin gene) in adulthood is the most potent modifier of disease severity. Thus, research has focused on elucidating pathways to increase g-globin expression in adulthood, as therapy for SCD. While SCD treatment strategies are focusing in the modulation of the globin genes (g-globin gene expression), other therapies need to be implemented early in the infant’s life to manage the severity of SCD clinical symptoms. Therefore, this presentation will focus on two different biological pathways that might lead into the development of new SCD therapeutic strategies. Click for more information
1750 Independence AvenueKansas City, Mo. 64106-14531-800-234-4847 | 816-654-7000